Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability in Head-to-Head Study
SNY is trading near its 52-week low of $43.32 (11% above the low).
Summary
Sanofi announced positive results from a head-to-head Phase 4 study, showing its Nuvaxovid COVID-19 vaccine had statistically significant better tolerability than Moderna's mNEXSPIKE. The study found Nuvaxovid resulted in lower systemic and local reactogenicity, with severe systemic symptoms more than 50% less frequent. This improved tolerability profile, which addresses a key reason for low vaccination uptake, could enhance Nuvaxovid's competitive position in the ongoing COVID-19 vaccine market. This news is distinct from the recent positive Phase 2 results for Sanofi's lunsekimig. Traders should monitor future sales data to assess if this tolerability advantage translates into increased market share for Nuvaxovid.
At the time of this announcement, SNY was trading at $48.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.3B. The 52-week trading range was $43.32 to $55.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.